Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Merck & Co., Inc. : Lawsuit Claims Merck Overstated Mumps Vaccine Effectiveness

share with twitter share with LinkedIn share with facebook
share via e-mail
06/22/2012 | 07:32pm CET
   By Jon Kamp 

Two former Merck & Co. Inc. (MRK) employees have sued the company in federal court alleging Merck overstated the effectiveness of a mumps vaccine for which the U.S. government paid hundreds of millions of dollars.

Merck--which stressed that none of these allegations relate to the safety of its product--said the lawsuit is "completely without merit", and that it plans to "vigorously defend itself." The Whitehouse Station, N.J., drug maker also noted that the U.S. Department of Justice has thus far declined to participate in the case after its own two-year probe.

Mumps is a contagious disease that causes symptoms like fever, headache and swollen salivary glands. It was a common illness for kids and young adults before childhood vaccinations became common decades ago, according to the Centers for Disease Control and Prevention, although there were outbreaks in 2006 and 2009. The agency says vaccines are the best way to prevent mumps.

Merck introduced the first vaccine 45 years ago, and since the 1970s it's been part of a combination product that also immunizes children against rubella and measles. According to the lawsuit--filed by former Merck virologists Stephen Krahling and Joan Wlochowski--the company allegedly defrauded the U.S. for more than a decade by hiding the fact the vaccine had become less effective.

As a result, the former employees say the government has long paid for a product that doesn't live up to Merck's claims. The lawsuit seeks a judgment against Merck equal to three times the damages suffered by the U.S., plus the maximum allowable award for the former employees under federal whistleblower laws.

The suit was first filed in 2010 in the U.S. District Court for the Eastern District of Pennsylvania. It was unsealed Thursday after the government declined to get involved in the case.

Merck confirmed Krahling and Wlochowski were former employees, but it said they haven't worked at the company for a decade.

"It's important to understand that none of the allegations in the complaint relate to the safety of M-M-R II"--the vaccine in question--"and we remain confident that M-M-R II helps protect against measles, mumps and rubella as described in the labeling for the vaccine," Merck said in a statement.

"M-M-R II continues to be recommended for routine administration to children by public health authorities around the world, including the U.S. Centers for Disease Control and Prevention and the U.S. Food and Drug Administration," the company said.

Merck doesn't specifically break out sales for the vaccine, but the company reported combined U.S. sales of $1.1 billion last year for that product and two other childhood vaccines. Merck shares recently traded up 1.9% to $40.19 and have risen 6.6% this year.

Write to Jon Kamp at [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK AND COMPANY
01:26pEISAI : Anticancer Agent LENVIMA Approved for Additional Indication of Unresecta..
03/23MERCK AND : Announces Appointment of Jennifer Zachary as General Counsel
03/23MERCK AND : Anticancer Agent LENVIMA® (lenvatinib mesylate) Approved for Additio..
03/22MERCK AND : Two States in Nigeria Interrupt Transmission of River Blindness
03/21Britain's use of copycat biotech drugs takes off while U.S. lags
03/21GlaxoSmithKline prescribes commercial reboot for pharma division
03/21GlaxoSmithKline prescribes commercial reboot for pharma division
03/21Tecentriq combo meets PFS endpoint in first-line squamous NSCLC
03/21MERCK AND : Tecentriq combo success boosts Roche in lung cancer
03/21MSD ANIMAL HEALTH : Receives Positive Opinion from European Medicines Agency for..
More news
News from SeekingAlpha
03/23Alzheon Files To Raise $80 Million In U.S. IPO 
03/23Eisai's Lenvima OK'd in Japan for liver cancer 
03/23Inovio's China Partnership License Agreement Should Be Cheered 
03/21FDA OKs Sun Pharma's Ilumya for plaque psoriasis 
03/20Biotechs Approaching New Waters 
Financials ($)
Sales 2018 41 711 M
EBIT 2018 13 779 M
Net income 2018 8 873 M
Debt 2018 13 131 M
Yield 2018 3,62%
P/E ratio 2018 16,07
P/E ratio 2019 13,28
EV / Sales 2018 3,77x
EV / Sales 2019 3,59x
Capitalization 144 B
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 66,5 $
Spread / Average Target 24%
EPS Revisions
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Roy D. Baynes Chief Medical Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY-5.08%144 004
JOHNSON & JOHNSON-8.83%335 598
NOVARTIS-7.31%207 583
PFIZER0.14%205 314
ROCHE HOLDING LTD.-12.37%196 669
AMGEN-2.57%122 085